Nektar Therapeutics reported $60.27M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 1.47B 5.38M Sep/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
Amgen USD 51.61B 250M Sep/2026
Baxter International USD 8.62B 6M Jun/2026
BioCryst Pharmaceuticals USD 395.61M 209K Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Cara Therapeutics USD 0 0 Mar/2025
Cipla INR 4.69B 874.1M Sep/2026
Dr.Reddys Laboratories INR 11.92B 284M Sep/2026
Eisai JPY 184.62B 19M Sep/2026
Eli Lilly USD 46.99B 872M Sep/2026
Gilead Sciences USD 23.82B 17M Sep/2026
GlaxoSmithKline GBP 21.7B 7.75B Sep/2026
Grifols EUR 9.95B 722.93M Dec/2025
Halozyme Therapeutics USD 2.94B 1.01B Sep/2026
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
MacroGenics USD 163.16M 94.44M Jun/2026
Merck USD 49.69B 1.39B Sep/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 38.38B 893M Sep/2026
Pfizer USD 60B 498M Sep/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
Takeda JPY 4.17T 245.32B Sep/2026
Teva Pharmaceutical Industries USD 12.68B 588M Sep/2026
Xencor USD 71.93M 5.61M Sep/2026